| Title |
SARS CoV-2 infection among patients using immunomodulatory therapies
|
|---|---|
| Published in |
Annals of the Rheumatic Diseases, August 2020
|
| DOI | 10.1136/annrheumdis-2020-218580 |
| Pubmed ID | |
| Authors |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
An error occurred while generating this chart. Please try again later.
No score history available for this output yet. Please try again later.
X Demographics
The data shown below were collected from the profiles of 34 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 18% |
| Spain | 3 | 9% |
| United Kingdom | 3 | 9% |
| Mexico | 3 | 9% |
| Ireland | 2 | 6% |
| Australia | 2 | 6% |
| Colombia | 1 | 3% |
| Philippines | 1 | 3% |
| Paraguay | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 10 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 24 | 71% |
| Practitioners (doctors, other healthcare professionals) | 5 | 15% |
| Scientists | 5 | 15% |
Mendeley demographics
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 116 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 14% |
| Other | 14 | 12% |
| Student > Bachelor | 11 | 9% |
| Student > Ph. D. Student | 10 | 9% |
| Student > Doctoral Student | 9 | 8% |
| Other | 21 | 18% |
| Unknown | 35 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 34% |
| Nursing and Health Professions | 9 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Environmental Science | 3 | 3% |
| Other | 12 | 10% |
| Unknown | 41 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2024.
All research outputs
#1,855,848
of 34,295,391 outputs
Outputs from Annals of the Rheumatic Diseases
#1,216
of 10,574 outputs
Outputs of similar age
#39,097
of 455,089 outputs
Outputs of similar age from Annals of the Rheumatic Diseases
#19
of 114 outputs
Altmetric has tracked 34,295,391 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,574 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.5. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 455,089 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 114 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.